BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 28570566)

  • 1. Targeting YAP/TAZ-TEAD protein-protein interactions using fragment-based and computational modeling approaches.
    Kaan HYK; Sim AYL; Tan SKJ; Verma C; Song H
    PLoS One; 2017; 12(6):e0178381. PubMed ID: 28570566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of TAZ-TEAD complex reveals a distinct interaction mode from that of YAP-TEAD complex.
    Kaan HYK; Chan SW; Tan SKJ; Guo F; Lim CJ; Hong W; Song H
    Sci Rep; 2017 May; 7(1):2035. PubMed ID: 28515457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
    Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
    Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecular dynamics simulations study of influence of Tyr422Ala mutation on transcriptional enhancer activation domain 4 (TEAD4) and transcription co-activators complexes.
    Niu RJ; Zheng QC; Zhang HX
    J Theor Biol; 2019 Jul; 472():27-35. PubMed ID: 30978352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Quinolinols as Activators of TEAD-Dependent Transcription.
    Pobbati AV; Mejuch T; Chakraborty S; Karatas H; Bharath SR; Guéret SM; Goy PA; Hahne G; Pahl A; Sievers S; Guccione E; Song H; Waldmann H; Hong W
    ACS Chem Biol; 2019 Dec; 14(12):2909-2921. PubMed ID: 31742995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
    Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
    Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein-Protein Interaction Disruptors of the YAP/TAZ-TEAD Transcriptional Complex.
    Pobbati AV; Rubin BP
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33352993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ.
    Mesrouze Y; Meyerhofer M; Bokhovchuk F; Fontana P; Zimmermann C; Martin T; Delaunay C; Izaac A; Kallen J; Schmelzle T; Erdmann D; Chène P
    Protein Sci; 2017 Dec; 26(12):2399-2409. PubMed ID: 28960584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of transgenic lines to monitor and manipulate Yap/Taz-Tead activity in zebrafish reveals both evolutionarily conserved and divergent functions of the Hippo pathway.
    Miesfeld JB; Link BA
    Mech Dev; 2014 Aug; 133():177-88. PubMed ID: 24560909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TEAD4-YAP/TAZ protein-protein interaction: expected similarities and unexpected differences.
    Hau JC; Erdmann D; Mesrouze Y; Furet P; Fontana P; Zimmermann C; Schmelzle T; Hofmann F; Chène P
    Chembiochem; 2013 Jul; 14(10):1218-25. PubMed ID: 23780915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leveraging Hot Spots of TEAD-Coregulator Interactions in the Design of Direct Small Molecule Protein-Protein Interaction Disruptors Targeting Hippo Pathway Signaling.
    Zhao B; Pobbati AV; Rubin BP; Stauffer S
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the YAP/TAZ-TEAD Transcriptional Complex in the Metabolic Control of TRAIL Sensitivity by the Mevalonate Pathway in Cancer Cells.
    El Yousfi Y; Mora-Molina R; López-Rivas A; Yerbes R
    Cells; 2023 Sep; 12(19):. PubMed ID: 37830584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorescence polarization assay for the identification and evaluation of inhibitors at YAP-TEAD protein-protein interface 3.
    Zhou W; Li Y; Song J; Li C
    Anal Biochem; 2019 Dec; 586():113413. PubMed ID: 31479631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy.
    Bokhovchuk F; Mesrouze Y; Izaac A; Meyerhofer M; Zimmermann C; Fontana P; Schmelzle T; Erdmann D; Furet P; Kallen J; Chène P
    FEBS J; 2019 Jun; 286(12):2381-2398. PubMed ID: 30903741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Celastrol as a Novel YAP-TEAD Inhibitor for Cancer Therapy by High Throughput Screening with Ultrasensitive
    Nouri K; Azad T; Ling M; Janse van Rensburg HJ; Pipchuk A; Shen H; Hao Y; Zhang J; Yang X
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31635084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.
    Zhou Z; Hu T; Xu Z; Lin Z; Zhang Z; Feng T; Zhu L; Rong Y; Shen H; Luk JM; Zhang X; Qin N
    FASEB J; 2015 Feb; 29(2):724-32. PubMed ID: 25384421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of AP-1 by YAP/TAZ contributes to cell proliferation and organ growth.
    Koo JH; Plouffe SW; Meng Z; Lee DH; Yang D; Lim DS; Wang CY; Guan KL
    Genes Dev; 2020 Jan; 34(1-2):72-86. PubMed ID: 31831627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and ligand-binding analysis of the YAP-binding domain of transcription factor TEAD4.
    Li Y; Liu S; Ng EY; Li R; Poulsen A; Hill J; Pobbati AV; Hung AW; Hong W; Keller TH; Kang C
    Biochem J; 2018 Jun; 475(12):2043-2055. PubMed ID: 29760238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.
    Hagenbeek TJ; Zbieg JR; Hafner M; Mroue R; Lacap JA; Sodir NM; Noland CL; Afghani S; Kishore A; Bhat KP; Yao X; Schmidt S; Clausen S; Steffek M; Lee W; Beroza P; Martin S; Lin E; Fong R; Di Lello P; Kubala MH; Yang MN; Lau JT; Chan E; Arrazate A; An L; Levy E; Lorenzo MN; Lee HJ; Pham TH; Modrusan Z; Zang R; Chen YC; Kabza M; Ahmed M; Li J; Chang MT; Maddalo D; Evangelista M; Ye X; Crawford JJ; Dey A
    Nat Cancer; 2023 Jun; 4(6):812-828. PubMed ID: 37277530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.